NewsAI-assisted

Cosette Pharmaceuticals Appoints Brad Leonard as VP of Generics Operations

Brad Leonard joins Cosette Pharmaceuticals as VP to lead generics growth and strategic expansion.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Feb 04, 2025Updated Jun 26, 2025 · 2 min read
Cosette Pharmaceuticals Appoints Brad Leonard as VP of Generics Operations
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

Cosette Pharmaceuticals has named Brad Leonard as its new Vice President of Generics Commercial Operations, bringing with him more than 30 years of industry expertise. Leonard, a seasoned leader in pharmaceuticals, will oversee sales, marketing, customer service, and demand planning for Cosette’s expanding generics portfolio. His previous leadership at Upsher-Smith Laboratories helped strengthen commercial strategies and financial performance, earning industry recognition for market impact. Cosette’s President and CEO, Apurva Saraf, expressed confidence in Leonard’s ability to drive innovation and foster new strategic partnerships, positioning the company for further success in the generics market.

Leonard shared his enthusiasm for joining Cosette at a time of significant growth, emphasizing his commitment to expanding market reach and improving accessibility for patients. He highlighted Cosette’s strong reputation for quality and innovation, stating that he looks forward to collaborating with the team to elevate commercial strategies and strengthen relationships with healthcare partners. With this appointment, Cosette aims to enhance its generics division, ensuring greater access to high-quality, cost-effective medicines for patients and providers alike.

TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →